Newsbenzinga
Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…